Working… Menu

A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02672501
Recruitment Status : Unknown
Verified February 2016 by Shanghai GeneChem Co., Ltd..
Recruitment status was:  Recruiting
First Posted : February 3, 2016
Last Update Posted : February 3, 2016
Information provided by (Responsible Party):
Shanghai GeneChem Co., Ltd.

No Study Results Posted on for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : June 2018
Estimated Study Completion Date : December 2019